Premium
Chimeric papillomavirus virus‐like particles induce a murine self‐antigen‐specific protective and therapeutic antitumor immune response
Author(s) -
Nieland John D.,
Da Silva Diane M.,
Velders Markwin P.,
de Visser Karin E.,
Schiller John T.,
Müller Martin,
Kast W. Martin
Publication year - 1999
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/(sici)1097-4644(19990501)73:2<145::aid-jcb1>3.0.co;2-5
Subject(s) - immune system , antigen , virus , adjuvant , immunization , virology , virus like particle , t cell , biology , immunology , cancer research , recombinant dna , gene , biochemistry
The use of chimeric virus‐like particles represents a new strategy for delivering tumor antigens to the immune system for the initiation of antitumor immune responses. Immunization of DBA/2 mice with the P1A peptide derived from the P815 tumor‐associated antigen P1A induced specific T‐cell tolerance, resulting in progression of a regressor P815 cell line in all animals. However, immunization with a human papillomavirus type 16 L1 virus‐like particle containing the P1A peptide in the absence of adjuvant induced a protective immune response in mice against a lethal tumor challenge with a progressor P815 tumor cell line. Additionally, we demonstrated that these chimeric virus‐like particles could be used therapeutically to suppress the growth of established tumors, resulting in a significant survival advantage for chimeric virus‐like particle‐treated mice compared with untreated control mice. Chimeric virus‐like particles can thus be used as a universal delivery vehicle for both tolerizing and antigenic peptides to induce a strong protective and therapeutic antigen‐specific antitumor immune response. J. Cell. Biochem. 73:145–152, 1999. © 1999 Wiley‐Liss, Inc.